Valuation : Precipio Inc

Market Cap 48.91M 42.2M 39.94M 36.18M 67.83M 4.67B 68.32M 473M 182M 2.38B 184M 180M 7.52B P/E 2024
-1.89x
P/E 2025 -102x
Enterprise Value 49.91M 43.06M 40.75M 36.92M 69.22M 4.77B 69.72M 482M 186M 2.42B 187M 183M 7.67B EV / Sales 2024
0.44x
EV / Sales 2025 1.72x
Free-Float
87.32%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Operating Officer 41 -
Chief Tech/Sci/R&D Officer 42 31/05/2017
Chief Executive Officer 54 27/06/2017
Director TitleAgeSince
Director/Board Member 54 27/06/2017
Director/Board Member 78 25/09/2017
Director/Board Member 67 07/11/2017
Change 5-day change 1-year change 3-year change Capi.($)
+20.04%-15.97% - - 48.91M
+0.87%-1.81%+20.83%-28.73% 16.73B
-1.77%+5.22%-35.05%+55.90% 1.75B
+0.08%-4.28%-28.36%+24.66% 893M
-3.05%-15.68%-58.77%-84.02% 808M
-0.05%-0.27%+63.36%-1.86% 778M
-2.56%-5.17%-38.85%-50.56% 637M
-5.26%-9.59%-43.32%-52.47% 560M
+3.41%-14.92%-44.30%-37.49% 450M
+2.02%+0.62%-7.77%-7.88% 397M
Average +1.37%-4.79%-19.14%-20.27% 2.56B
Weighted average by Cap. +0.34%-2.06%+8.33%-22.24%

Financials

2024 2025
Net sales 18.53M 15.99M 15.13M 13.71M 25.7M 1.77B 25.89M 179M 69.04M 900M 69.57M 68.06M 2.85B 24.05M 20.75M 19.64M 17.79M 33.36M 2.3B 33.6M 232M 89.59M 1.17B 90.28M 88.32M 3.7B
Net income -4.29M -3.7M -3.5M -3.17M -5.95M -410M -5.99M -41.45M -15.98M -208M -16.1M -15.76M -659M -363K -313K -296K -269K -503K -34.68M -507K -3.51M -1.35M -17.63M -1.36M -1.33M -55.78M
Net Debt -136K -117K -111K -101K -189K -12.99M -190K -1.31M -507K -6.6M -511K -499K -20.9M 1M 865K 818K 741K 1.39M 95.73M 1.4M 9.68M 3.73M 48.66M 3.76M 3.68M 154M
Logo Precipio Inc
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Employees
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!